Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

21.4%

3 terminated/withdrawn out of 14 trials

Success Rate

70.0%

-16.5% vs industry average

Late-Stage Pipeline

21%

3 trials in Phase 3/4

Results Transparency

86%

6 of 7 completed trials have results

Key Signals

2 recruiting6 with results

Enrollment Performance

Analytics

Phase 2

5(45.5%)

Early Phase 1

2(18.2%)

Phase 4

2(18.2%)

Phase 3

1(9.1%)

Phase 1

1(9.1%)

11Total

Phase 2(5)

Early Phase 1(2)

Phase 4(2)

Phase 3(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT01246765Recruiting

National Pregnancy Registry for Psychiatric Medications

Role: collaborator

NCT05223829Phase 1Active Not Recruiting

Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder

Role: collaborator

NCT05366751Phase 2Terminated

A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor

Role: lead

NCT06580444Phase 2Not Yet Recruiting

Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study

Role: collaborator

NCT05173012Phase 2Completed

Study to Evaluate SAGE-324 in Participants With Essential Tremor

Role: lead

NCT05543746Completed

Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression

Role: collaborator

NCT05314153Early Phase 1Completed

Effects Zulresso on Postpartum Psychosis

Role: collaborator

NCT05254405Phase 4Recruiting

An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder

Role: collaborator

NCT04305275Phase 2Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor

Role: lead

NCT04928703Early Phase 1Completed

Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers

Role: collaborator

NCT04537806Phase 3Terminated

A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)

Role: lead

NCT02277106Phase 2Completed

Evaluate SAGE-547 in Participants With Essential Tremor

Role: lead

NCT04025502Completed

Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects

Role: collaborator

NCT04273191Phase 4Withdrawn

A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)

Role: lead

All 14 trials loaded